

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Scope for guideline update (starting 2026)

Diabetes in pregnancy: management from preconception to the postnatal period

15/01/2026

NICE is updating its guideline on [diabetes in pregnancy: management from preconception to the postnatal period](#) (NG3).

The update will be developed using the methods and processes in [developing NICE guidelines: the manual](#).

Who the guideline update covers

The update will focus on women, trans men and non-binary people with type 1 diabetes who are:

- planning to become pregnant
- pregnant
- in the postnatal period.

This guideline update will not cover people with:

- type 2 diabetes
- gestational diabetes.

Equality considerations

A new [equality and health inequalities assessment](#) has been completed.

Settings

The update will cover the same settings as the current guideline, which are all settings where NHS funded care is provided or commissioned.

Activities, services or aspects of care covered by the guideline update

We will consider making recommendations or updating existing recommendations on blood glucose monitoring and management in:

- preconception planning and care
- antenatal care
- intrapartum care
- postnatal care

Recommendations that are being retained from the current guideline may be revised to update language, reflect current policy or practice, and to ensure consistency with new content.

See the [section on recommendations we plan to retain](#).

This guideline update will not cover:

- neonatal care.

Draft review question

We have developed the following draft review question. This may change during guideline development, but the area covered will remain as listed in the final scope.

The area covered and draft question will be used to develop a more detailed review protocol.

Blood glucose management in people with type 1 diabetes in the pre-conception, antenatal and postpartum period

1. For women, trans men and non-binary people with type 1 diabetes who are planning to become pregnant, are pregnant, or are in the postpartum period, what is the effectiveness and cost effectiveness of hybrid closed

loop systems for improving maternal, fetal and neonatal outcomes compared with standard practice?

Economic aspects

We will take economic aspects into account when making recommendations.

NICE guidance and quality standards that may be affected by this guideline update

- [Type 1 diabetes in adults: diagnosis and management](#) (2015, 2022). NICE guideline NG17
- [Type 1 diabetes in adults](#) (2023). NICE quality standard 208
- [Diabetes in pregnancy](#) (2016, 2023). NICE quality standard 109

Incorporating NICE technology appraisals

NICE technology appraisal guidance will be incorporated into the guideline where relevant. For further details, see our [web page on bringing our guidance together by topic](#).

NICE has published a technology appraisal on [hybrid closed loop systems for managing blood glucose levels in type 1 diabetes](#) (2023); NICE technology appraisal guidance 943

Recommendations we plan to retain

We will not be reviewing the evidence on the following:

Preconception planning and care

- information about outcomes and risks for mother and baby
- the importance of planning pregnancy and the role of contraception
- diet, dietary supplements and body weight
- monitoring ketones before pregnancy
- target blood glucose and HbA1c levels before pregnancy
- safety of medicines for diabetes before and during pregnancy

- safety of medicines for complications of diabetes before and during pregnancy
- making access to preconception care easier
- education and advice
- retinal assessment before pregnancy
- renal assessment before pregnancy

Gestational diabetes

- risk assessment, testing and diagnosis
- interventions

Antenatal care

- target blood glucose levels
- monitoring HbA1c
- managing blood glucose during pregnancy for women, trans men and non-binary people with type 2 or gestational diabetes
- ketone testing and diabetic ketoacidosis
- retinal assessment during pregnancy
- renal assessment during pregnancy
- preventing pre-eclampsia
- detecting congenital malformations
- monitoring fetal growth and wellbeing
- organisation of antenatal care
- preterm labour

Intrapartum care

- timing and mode of birth
- anaesthesia

Neonatal care

- initial assessment and criteria for admission to intensive or special care
- preventing and assessing neonatal hypoglycaemia

Postnatal care

- blood glucose management for women, trans men and non-binary people with type 2 or gestational diabetes
- breastfeeding
- information and follow-up after birth.

We plan to retain the recommendations in these areas, although they may be revised to update language, reflect current policy or practice, and to ensure consistency.

Further information

The guideline update is expected to be published in August 2026.

To follow the progress of the update, see the [guideline in development page](#).

Our website has information about [how NICE guidelines are developed](#).

NICE guidelines cover health and care in England. Decisions on how they apply in other UK countries are made by ministers in the [Welsh Government](#), [Scottish Government](#) and [Northern Ireland Executive](#).

© NICE 2026. All rights reserved. Subject to [Notice of rights](#).